Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aqua Pharmaceuticals, LLC Appoints Ted White as COO, Mark Boyer as Director of Finance

Published: Tuesday, February 12, 2013
Last Updated: Tuesday, February 12, 2013
Bookmark and Share
White moves to the new role from his previous position as Vice President of Sales, while Boyer advances from his former position as Controller.

As COO, White will be responsible for overseeing the daily operation of Aqua and developing business strategies, serving as second-in-command to the company’s President and CEO, Craig Ballaron.

“I can always depend on Ted to be ahead of the curve,” said Ballaron. “He’s a fantastic manager, and his combination of sales savvy and steadfast leadership have helped him move up quickly within the company.”

White joined Aqua in 2011 following a successful 21-year sales career with Novartis Pharmaceutical Corporation, where he led sales teams in new product launches and executed tactics for multiple billion-dollar brands. In July 2010, PharmaVoice magazine named him one of the top 100 inspirational leaders in the health sciences field.

As the new Director of Finance, Boyer, who is a licensed CPA, will manage the company’s budget and lay out operational fiscal policies.

“Having someone with a solid, analytical understanding of both numbers and the pharmaceutical industry in general is invaluable to Aqua,” said Ballaron. “As Controller, Mark demonstrated a knack for both. He’s adept at data analysis and managing corporate funds, so moving to the role of Director of Finance was a natural progression.”

Prior to joining Aqua in 2010, Boyer worked as a Senior Accountant for Teleflex Incorporated’s ARROW International division, where he was responsible for financial reporting, Sarbanes-Oxley compliance and fixed-asset management.

“This is a dynamic time of growth and change for Aqua,” said Ballaron. “I am excited to help write the next phase in our company’s history with Ted and Mark at my side.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!